Skip to main content

Table 1 Demographic and clinical characteristics of Tasmanian CKD patients participating in the study (n = 27)

From: Tryptophan metabolism, its relation to inflammation and stress markers and association with psychological and cognitive functioning: Tasmanian Chronic Kidney Disease pilot study

Parameter

Frequency (%) or Mean ± SD [Range]

Male (%)

18 (67 %)

Age (years)

76.4 ± 7.3 [60–87]

Education > Year 12

9 (33 %)

Living with a partner

22 (81 %)

Retired

23 (85 %)

Smoker, current or former

16 (59 %)

Body mass index (kg/m2)

29.8 ± 5.1 [21.5–42.4]

Serum creatinine (μmol/L)

336.4 ± 178.2 [121–863]

eGFR (mL/min/1.73 m2)

17.0 ± 8.4 [5–36]

CKD

 Stage 3b

3 (11 %)

 Stage 4

10 (37 %)

 Stage 5 (non-dialysed)

7 (26 %)

 Stage 5 (haemodialysis)

7 (26 %)

Depression score (PHQ-9)

3.5 ± 3.5 [0–14]

Anxiety score (BAI)

7.2 ± 6.4 [0–25]

Cognitive functioning (in KDQOL-SF 1.3)

86.2 ± 15.5 [46.7–100]

≥3 comorbidities

14 (52 %)

Diabetes mellitus

7 (26 %)

Hypertension

21 (78 %)

Atherosclerotic heart disease

9 (33 %)

Congestive heart failure

9 (33 %)

Peripheral vascular disease

7 (26 %)

Prescribed antidepressants

3 (11 %)

Prescribed ACE inhibitors

8 (30 %)

Prescribed Angiotensin II Receptor Blockers

8 (30 %)

Prescribed statins

18 (67 %)

Prescribed antibiotics

2 (7 %)

  1. Abbreviations: ACE angiotensin-converting enzyme, BAI, Beck Anxiety Inventory, CKD chronic kidney disease, eGFR estimated glomerular filtration rate, KDQOL-SF, Kidney Disease Quality of Life short-form, PHQ-9, Patient Health Questionnaire